Baidu
map

NEJM:糖尿病和稳定型缺血性心脏病患者的肌钙蛋白和心血管事件

2015-08-13 MedSci MedSci原创

    肌钙蛋白浓度被用来确定急性冠脉综合征的哪些患者将受益于紧急血运重建。研究人员推测,这也可能会用于病情稳定型缺血性心脏病患者以确定心血管事件高风险的患者谁也可能从冠脉血运重建中获益。    研究人员使用高灵敏度检测方法测量了基线的2285例同时患有2型糖尿病和病情稳定型缺血性心脏病患者的心肌肌钙蛋白T浓度,并招募了这些患者参加了2型糖尿病旁路血管成形术

肌钙蛋白浓度被用来确定急性冠脉综合征的哪些患者将受益于紧急血运重建。研究人员推测,这也可能会用于病情稳定型缺血性心脏病患者以确定心血管事件高风险的患者谁也可能从冠脉血运重建中获益。

研究人员使用高灵敏度检测方法测量了基线的2285例同时患有2型糖尿病和病情稳定型缺血性心脏病患者的心肌肌钙蛋白T浓度,并招募了这些患者参加了2型糖尿病旁路血管成形术血运重建研究。研究人员测试了肌钙蛋白T浓度与心血管原因,心肌梗死或卒中死亡的复合终点之间的关联;与那些具有正常肌钙蛋白T浓度(<14ng/L)患者相比,研究人员评估随机分配具有异常肌钙蛋白T浓度(≥14ng/L)的患者来是否可以提高血运重建来降低复合终点发生率。

在2285例患者中,在基线时,2277(99.6%)例患者检测到肌钙蛋白T浓度≥3纳克每升,897(39.3%)例患者有正常的肌钙蛋白T浓度。在基线时有异常肌钙蛋白T浓度的患者5年时复合终点的发生率为27.1%,那些正常基线肌钙蛋白T浓度的患者发生率为12.9%。在模型中,研究人员对心血管危险因素,糖尿病的严重程度,心电图异常,冠状动脉分析进行了调整,其中异常肌钙蛋白T浓度的患者复合终点危险比为1.85(95%置信区间[Cl],1.48〜2.32;P<0.001)。在异常肌钙蛋白T浓度患者中,与单独药物治疗相比,随机分配提高了血管重建,但并没有减少复合终点的发生率(风险比,0.96;95%Cl,0.74〜1.25)。

心肌肌钙蛋白T浓度是2型糖尿病和稳定型缺血性心脏病患者由于心血管,心肌梗死或卒中死亡的独立预测因子。14ng/L或更高的异常肌钙蛋白T值不能确定亚组患者哪些可以受益于随机分配来提高冠脉血运重建。

原文链接:

Brendan M. Everett,Maria Mori Brooks, Helen E.A. Vlachos,et al.Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes,NEJM,2015.8.13

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643365, encodeId=b56116433657d, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jun 12 07:31:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662562, encodeId=979e1662562a6, content=<a href='/topic/show?id=e1cae5295f9' target=_blank style='color:#2F92EE;'>#稳定型缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75295, encryptionId=e1cae5295f9, topicName=稳定型缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f725427387, createdName=12498710m19暂无昵称, createdTime=Mon May 09 16:31:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892668, encodeId=074518926685a, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 31 17:31:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803343, encodeId=fdc9180334334, content=<a href='/topic/show?id=8b44e528972' target=_blank style='color:#2F92EE;'>#稳定型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75289, encryptionId=8b44e528972, topicName=稳定型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Jan 14 01:31:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318348, encodeId=74ec131834886, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Aug 15 00:31:00 CST 2015, time=2015-08-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643365, encodeId=b56116433657d, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jun 12 07:31:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662562, encodeId=979e1662562a6, content=<a href='/topic/show?id=e1cae5295f9' target=_blank style='color:#2F92EE;'>#稳定型缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75295, encryptionId=e1cae5295f9, topicName=稳定型缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f725427387, createdName=12498710m19暂无昵称, createdTime=Mon May 09 16:31:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892668, encodeId=074518926685a, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 31 17:31:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803343, encodeId=fdc9180334334, content=<a href='/topic/show?id=8b44e528972' target=_blank style='color:#2F92EE;'>#稳定型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75289, encryptionId=8b44e528972, topicName=稳定型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Jan 14 01:31:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318348, encodeId=74ec131834886, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Aug 15 00:31:00 CST 2015, time=2015-08-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643365, encodeId=b56116433657d, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jun 12 07:31:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662562, encodeId=979e1662562a6, content=<a href='/topic/show?id=e1cae5295f9' target=_blank style='color:#2F92EE;'>#稳定型缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75295, encryptionId=e1cae5295f9, topicName=稳定型缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f725427387, createdName=12498710m19暂无昵称, createdTime=Mon May 09 16:31:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892668, encodeId=074518926685a, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 31 17:31:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803343, encodeId=fdc9180334334, content=<a href='/topic/show?id=8b44e528972' target=_blank style='color:#2F92EE;'>#稳定型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75289, encryptionId=8b44e528972, topicName=稳定型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Jan 14 01:31:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318348, encodeId=74ec131834886, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Aug 15 00:31:00 CST 2015, time=2015-08-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643365, encodeId=b56116433657d, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jun 12 07:31:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662562, encodeId=979e1662562a6, content=<a href='/topic/show?id=e1cae5295f9' target=_blank style='color:#2F92EE;'>#稳定型缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75295, encryptionId=e1cae5295f9, topicName=稳定型缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f725427387, createdName=12498710m19暂无昵称, createdTime=Mon May 09 16:31:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892668, encodeId=074518926685a, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 31 17:31:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803343, encodeId=fdc9180334334, content=<a href='/topic/show?id=8b44e528972' target=_blank style='color:#2F92EE;'>#稳定型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75289, encryptionId=8b44e528972, topicName=稳定型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Jan 14 01:31:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318348, encodeId=74ec131834886, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Aug 15 00:31:00 CST 2015, time=2015-08-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1643365, encodeId=b56116433657d, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Jun 12 07:31:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662562, encodeId=979e1662562a6, content=<a href='/topic/show?id=e1cae5295f9' target=_blank style='color:#2F92EE;'>#稳定型缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75295, encryptionId=e1cae5295f9, topicName=稳定型缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02f725427387, createdName=12498710m19暂无昵称, createdTime=Mon May 09 16:31:00 CST 2016, time=2016-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892668, encodeId=074518926685a, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Tue May 31 17:31:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1803343, encodeId=fdc9180334334, content=<a href='/topic/show?id=8b44e528972' target=_blank style='color:#2F92EE;'>#稳定型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75289, encryptionId=8b44e528972, topicName=稳定型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Thu Jan 14 01:31:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318348, encodeId=74ec131834886, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sat Aug 15 00:31:00 CST 2015, time=2015-08-15, status=1, ipAttribution=)]

相关资讯

JCI:增加肠促胰素分泌细胞数目,促进胰岛素的分泌

肠促胰岛素GLP-1有很强的促进胰岛素分泌的作用,以GLP-1为基础的药物已经广泛用于2型糖尿病的治疗。这些药物包括,GLP-1受体激动剂和DPPVI抑制剂。临床中,以GLP-1为基础的治疗可以改善T2DM的血糖情况,以广泛被认可。但是,这些药物并不是通过模拟生理性的与饮食相关的GLP-1浓度的升降情况,来增加胰岛素分泌的。文献报道,肠道中的GLP-1分泌细胞L细胞起源于早期的分泌腺祖细胞。这些祖

Diabetes Care:积极治疗非酒精性脂肪肝降低T2DM发病率

目前,有关评估非酒精性脂肪肝(NAFLD)对2型糖尿病(T2DM)长期影响的研究很少,此外改善NAFLD是否可减少T2DM发病率,还只是推测,目前并无相关研究对此进行验证。本研究,对改善NAFLD和T2DM发生率的相关性进行评估。研究者在2000至2012年间,一共招募4604名受试者入组,这些受试者的两次体检间隔要>10年。排除标准是,乙型肝炎病毒表面抗原阳性,丙型肝炎病毒抗体阳性,酒精摄

Lancet Diab & Endo:Roux-en-Y胃旁路术治疗T2DM

背景:治疗T2DM的传统方法疗效有限,本研究旨在评估除了强化生活方式干预和药物治疗外,Roux-en-Y胃旁路术治疗T2DM的疗效与风险。 方法:研究

AJM:中国T2DM患者心血管危险因素控制状况令人担忧

糖尿病、高血压和脂质异常被证明都可以增加心血管疾病风险。然而,传统的2型糖尿病管理模式主要关注血糖控制,强有力的证据支持高血压和脂质异常的综合管理可以降低心血管疾病风险。为了评估2型糖尿病患者中血糖、血压和血脂(3Bs)的控制水平,并探讨医院类型、医师专业、治疗模式和患者信息对临床结局的影响,来自北京大学人民医院纪立农教授及其团队进行了一项研究,该研究发现中国T2DM患者心

Diabetes Care:SGLT-2抑制剂Empagliflozin添加胰岛素控制不佳的肥胖T2DM患者取得较好疗效(EMPA-REG MDI研究)

接受大剂量胰岛素每日多次注射(MDI)仍控制不良的肥胖2型糖尿病患者,在胰岛素基础上叠加安慰剂(n=189)、Empagliflozin(一种 SGLT-2抑制剂)10mg(n=187)或25mg(n=190)治疗52周。主要疗效终点是18周时HbA1c水平,同时观察低血糖及其他不良反应的发生。结果表明,对于这个非常难治的患者群,叠加Empagliflozin改善了血糖控制,患者体重减轻、胰岛素

Diabetes Care:胰岛素敏感性可预测青少年 T2DM 患者早期肾脏损伤

当前,糖尿病肾病仍然是终末期肾脏疾病最常见的病因,也是 2 型糖尿病(T2DM)患者死亡的主要原因之一。胰岛素敏感性是成年 2 型糖尿病患者肾脏健康的一个重要决定因素,但是青少年 2 型糖尿病患者这方面的资料有限。为此,来自美国科罗拉多大学医学院的 Petter Bjornstad 教授及其团队进行了一项研究,探讨青少年 2 型糖尿病患者胰岛素敏感性与糖尿病肾病早期标志物之间的关系。该研究结果在线

Baidu
map
Baidu
map
Baidu
map